Prague (ots) – The SHARP-study has shown that lowering LDL cholesterol with ezetimibe/simvastatin leads to a significant reduction in major atherosclerotic events among CKD-patients. Whether it also has a favourable effect on renal disease progression was another of the issues addressed by the SHARP study [abstract no. 2509]. In the ezetimibe/simvastatin group, fewer patients reached [...]
Tag Archive > Cardiovascular Death
Mortality Data Presented for Patients Treated with Efient(R)/Effient(R) (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery
Chicago, November 16 (ots/PRNewswire) – New results from an observational substudy from TRITON-TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Efient(R)/Effient(R) (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix(R) (clopidogrel) (2.3 [...]
Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent Atrial Fibrillation
Paris, May 12, 2010 (ots/PRNewswire) – Sanofi-aventis announced today the initiation of a multinational, randomized, double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10,000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm [...]
New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
Paris, and Princeton, New Jersey (ots/PRNewswire) – -No added benefit on the composite primary end-point with the higher dose when entire ACS study population considered- -Important new findings with higher loading dose of PLAVIX(R) for heart patients undergoing coronary angioplasty (PCI)- Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical [...]
Diabetes Patients With High Triglycerides and Low HDL Cholesterol get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study
Sydney (ots/PRNewswire) – Fenofibrate treatment reduces cardiovascular disease (CVD) risk (defined by total cardiovascular events: the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularization) in patients with type 2 diabetes and atherogenic dyslipidemia, that is, the combination of high triglyceride (2.3 mmol/L-200mg/dL or higher) and low high-density lipoprotein (HDL) cholesterol (
RecordAF Registry Will Provide First Global Insight Into Real Life Management of Atrial Fibrillation – A Major Cause of Cardiovascular Death and Hospitalization
New Orleans, November 11 (ots/PRNewswire) – – Baseline Data from RecordAF Presented at American Heart Association’s Scientific Sessions Today Baseline data from the REgistry on Cardiac rhythm disORDers – an international, observational, prospective survey assessing the control of Atrial Fibrillation (RecordAF) – were presented today during the Scientific Sessions of the American Heart Association Congress [...]
